Padala SA and Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A: Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87. 2020. View Article : Google Scholar : PubMed/NCBI

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024. View Article : Google Scholar : PubMed/NCBI

Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R and O'Brien T: Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 82:529–542. 2022. View Article : Google Scholar : PubMed/NCBI

Musaddaq B, Musaddaq T, Gupta A, Ilyas S and von Stempel C: Renal cell carcinoma: The evolving role of imaging in the 21st century. Semin Ultrasound CT MR. 41:344–350. 2020. View Article : Google Scholar : PubMed/NCBI

Scosyrev E, Messing EM, Sylvester R and Van Poppel H: Exploratory subgroup analyses of renal function and overall survival in european organization for research and treatment of cancer randomized trial of Nephron-sparing surgery versus radical nephrectomy. Eur Urol Focus. 3:599–605. 2017. View Article : Google Scholar : PubMed/NCBI

Goswami PR, Singh G, Patel T and Dave R: The WHO 2022 classification of renal neoplasms (5th Edition): Salient updates. Cureus. 16:e584702024.PubMed/NCBI

Didwaniya N, Edmonds RJ, Fang X, Silberstein PT and Subbiah S: Survival outcomes in metastatic renal carcinoma based on histological subtypes: SEER database analysis. J Clin Oncol. 29:381. 2011. View Article : Google Scholar

Morais C, Gobe G, Johnson DW and Healy H: Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis. 15:412–425. 2010. View Article : Google Scholar : PubMed/NCBI

Toth C, Funke S, Nitsche V, Liverts A, Zlachevska V, Gasis M, Wiek C, Hanenberg H, Mahotka C, Schirmacher P and Heikaus S: The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): The crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling. Cell Commun Signal. 15:162017. View Article : Google Scholar : PubMed/NCBI

Yang WZ, Zhou H and Yan Y: XIAP underlies apoptosis resistance of renal cell carcinoma cells. Mol Med Rep. 17:125–130. 2018.PubMed/NCBI

Wang L, Fu B, Hou DY, Lv YL, Yang G, Li C, Shen JC, Kong B, Zheng LB, Qiu Y, et al: PKM2 allosteric converter: A self-assembly peptide for suppressing renal cell carcinoma and sensitizing chemotherapy. Biomaterials. 296:1220602023. View Article : Google Scholar : PubMed/NCBI

Diamond E, Molina AM, Carbonaro M, Akhtar NH, Giannakakou P, Tagawa ST and Nanus DM: Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Crit Rev Oncol Hematol. 96:518–526. 2015. View Article : Google Scholar : PubMed/NCBI

Saliby RM, Saad E, Kashima S, Schoenfeld DA and Braun DA: Update on biomarkers in renal cell carcinoma. Am Soc Clin Oncol Educ Book. 44:e4307342024. View Article : Google Scholar : PubMed/NCBI

Lam JS, Pantuck AJ, Belldegrun AS and Figlin RA: Protein expression profiles in renal cell carcinoma: Staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 13((2 Pt 2)): 703s–708s. 2007. View Article : Google Scholar : PubMed/NCBI

Lee JN, Chun SY, Ha YS, Choi KH, Yoon GS, Kim HT, Kim TH, Yoo ES, Kim BW and Kwon TG: Target molecule expression profiles in metastatic renal cell carcinoma: Development of individual targeted therapy. Tissue Eng Regen Med. 13:416–427. 2016. View Article : Google Scholar : PubMed/NCBI

Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al: Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol. 23:2763–2771. 2005. View Article : Google Scholar : PubMed/NCBI

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, et al: External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. Lancet Oncol. 14:141–148. 2013. View Article : Google Scholar : PubMed/NCBI

Kattan MW, Reuter V, Motzer RJ, Katz J and Russo P: A Postoperative prognostic nomogram for renal cell carcinoma. J Urol. 166:63–67. 2001. View Article : Google Scholar : PubMed/NCBI

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced Renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, et al: Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 384:1289–1300. 2021. View Article : Google Scholar : PubMed/NCBI

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019. View Article : Google Scholar : PubMed/NCBI

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al: Pembrolizumab plus axitinib versus sunitinib for advanced Renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019. View Article : Google Scholar : PubMed/NCBI

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, et al: Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. The Lancet. 393:2404–2415. 2019. View Article : Google Scholar

Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer TM, Jain RK, Somer B, Lam ET, Kochenderfer MD, Molina A, et al: Safety and efficacy of nivolumab in patients with advanced Non-clear cell renal cell carcinoma: Results from the Phase IIIb/IV CheckMate 374 study. Clin Genitourin Cancer. 18:461–468.e3. 2020. View Article : Google Scholar : PubMed/NCBI

Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, et al: Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 10:e0038442022. View Article : Google Scholar : PubMed/NCBI

Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, et al: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, Open-label, phase 3 trial. The Lancet. 402:185–195. 2023. View Article : Google Scholar

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, et al: Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 384:829–841. 2021. View Article : Google Scholar : PubMed/NCBI

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, et al: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 385:683–694. 2021. View Article : Google Scholar : PubMed/NCBI

Monjaras-Avila CU, Lorenzo-Leal AC, Luque-Badillo AC, D'Costa N, Chavez-Muñoz C and Bach H: The tumor immune microenvironment in clear cell renal cell carcinoma. Int J Mol Sci. 24:79462023. View Article : Google Scholar : PubMed/NCBI

Karras P, Black JRM, McGranahan N and Marine JC: Decoding the interplay between genetic and Non-genetic drivers of metastasis. Nature. 629:543–554. 2024. View Article : Google Scholar : PubMed/NCBI

Ucche S and Hayakawa Y: Immunological aspects of cancer cell metabolism. Int J Mol Sci. 25:52882024. View Article : Google Scholar : PubMed/NCBI

Bucciol G, Delafontaine S, Meyts I and Poli C: Inborn errors of immunity: A field without frontiers. Immunol Rev. 322:15–27. 2024. View Article : Google Scholar : PubMed/NCBI

Kramer G, Blair T, Bambina S, Kaur AP, Alice A, Baird J, Friedman D, Dowdell AK, Tomura M, Grassberger C, et al: Fluorescence tracking demonstrates T cell recirculation is transiently impaired by radiation therapy to the tumor. Sci Rep. 14:119092024. View Article : Google Scholar : PubMed/NCBI

Tan D, Miao D, Zhao C, Shi J, Lv Q, Xiong Z, Yang H and Zhang X: Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma. BMC Cancer. 23:2642023. View Article : Google Scholar : PubMed/NCBI

Wu Y and Li X: Senescence gene expression in clear cell renal cell carcinoma: Role of tumor immune microenvironment and senescence-associated survival prediction. Medicine (Baltimore). 102:e352222023. View Article : Google Scholar : PubMed/NCBI

Zhang Q, Lin B, Chen H, Ye Y, Huang Y, Chen Z and Li J: Lipid Metabolism-related gene expression in the immune microenvironment predicts prognostic outcomes in renal cell carcinoma. Front Immunol. 14:13242052023. View Article : Google Scholar : PubMed/NCBI

Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M and Mafakher L: Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 39:2022–vol3. 2022.PubMed/NCBI

Mickisch G, Bier H, Bergler W, Bak M, Tschada R and Alken P: P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int. 45:170–176. 2010. View Article : Google Scholar : PubMed/NCBI

Guo Y, Schoell MC and Freeman RS: The von Hippel-lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIMEL. Oncogene. 28:18642009. View Article : Google Scholar : PubMed/NCBI

Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Sarper I, Ketterer K, Henke T, Eichelberg C, et al: Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget. 11:237–249. 2020. View Article : Google Scholar : PubMed/NCBI

Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, et al: The intratumoral balance between metabolic and immunologic gene expression is associated with Anti-PD-1 response in patients with renal cell carcinoma. Cancer Immunol Res. 4:726–733. 2016. View Article : Google Scholar : PubMed/NCBI

Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N: Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160:48–61. 2015. View Article : Google Scholar : PubMed/NCBI

Möller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, et al: Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint Therapy-naive clear cell renal cell cancer. Int Urol Nephrol. 53:2493–2503. 2021. View Article : Google Scholar : PubMed/NCBI

Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, et al: Tumour grade significantly correlates with total dysfunction of tumour Tissue-infiltrating lymphocytes in renal cell carcinoma. Sci Rep. 10:62202020. View Article : Google Scholar : PubMed/NCBI

Wang Y, Yin C, Geng L and Cai W: Immune infiltration landscape in clear cell renal cell carcinoma implications. Front Oncol. 10:4916212021. View Article : Google Scholar : PubMed/NCBI

Sabrina S, Takeda Y, Kato T, Naito S, Ito H, Takai Y, Ushijima M, Narisawa T, Kanno H, Sakurai T, et al: Initial myeloid cell status is associated with clinical outcomes of renal cell carcinoma. Biomedicines. 11:12962023. View Article : Google Scholar : PubMed/NCBI

Liu B, Chen X, Zhan Y, Wu B and Pan S: Identification of a gene signature for renal cell Carcinoma-associated fibroblasts mediating cancer progression and affecting prognosis. Front Cell Dev Biol. 8:6046272021. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Chen X, Fu Q, Wang F, Zhou X, Xiang J, He N, Hu Z and Jin X: Comprehensive analysis of pyroptosis regulators and tumor immune microenvironment in clear cell renal cell carcinoma. Cancer Cell Int. 21:6672021. View Article : Google Scholar : PubMed/NCBI

Ballesteros PÁ, Chamorro J, Román-Gil MS, Pozas J, Gómez Dos Santos V, Granados ÁR, Grande E, Alonso-Gordoa T and Molina-Cerrillo J: Molecular mechanisms of resistance to immunotherapy and antiangiogenic treatments in clear cell renal cell carcinoma. Cancers. 13:59812021. View Article : Google Scholar : PubMed/NCBI

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al: Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and Non-small-cell lung cancer. Ann Oncol. 29:1437–1444. 2018. View Article : Google Scholar : PubMed/NCBI

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 359:91–97. 2018. View Article : Google Scholar : PubMed/NCBI

Xing Y and Hogquist KA: T-cell tolerance: Central and peripheral. Cold Spring Harb Perspect Biol. 4:a0069572012. View Article : Google Scholar : PubMed/NCBI

Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, et al: Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 39:632–648.e8. 2021. View Article : Google Scholar : PubMed/NCBI

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, et al: The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res. 6:758–765. 2018. View Article : Google Scholar : PubMed/NCBI

Pichler R, Siska PJ, Tymoszuk P, Martowicz A, Untergasser G, Mayr R, Weber F, Seeber A, Kocher F, Barth DA, et al: A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma. Front Immunol. 14:10951952023. View Article : Google Scholar : PubMed/NCBI

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 4:1721–1728. 2018. View Article : Google Scholar : PubMed/NCBI

Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, Liu J and Yu Y: Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma. Front Immunol. 12:6533582021. View Article : Google Scholar : PubMed/NCBI

Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Okumi M, Ishida H and Tanabe K: Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 38:526–532. 2020.

Noguchi G, Nakaigawa N, Umemoto S, Kobayashi K, Shibata Y, Tsutsumi S, Yasui M, Ohtake S, Suzuki T, Osaka K, et al: C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Cancer Chemother Pharmacol. 86:75–85. 2020. View Article : Google Scholar : PubMed/NCBI

Yano Y, Ohno T, Komura K, Fukuokaya W, Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Yamazaki S, et al: Serum C-reactive protein level predicts overall survival for clear cell and Non-clear cell renal cell carcinoma treated with ipilimumab plus nivolumab. Cancers. 14:56592022. View Article : Google Scholar : PubMed/NCBI

Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M, Grimm MO, Fujii Y, Umeyama Y, Huang B, et al: Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: Long-term follow-up results from JAVELIN renal 101. ESMO Open. 7:1005642022. View Article : Google Scholar : PubMed/NCBI

Kim JH, Kim GH, Ryu YM, Kim SY, Kim HD, Yoon SK, Cho YM and Lee JL: Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Front Oncol. 12:9695692022. View Article : Google Scholar : PubMed/NCBI

Sammarco E, Rossetti M, Salfi A, Bonato A, Viacava P, Masi G, Galli L and Faviana P: Tumor microenvironment and clinical efficacy of first line Immunotherapy-based combinations in metastatic renal cell carcinoma. Med Oncol. 41:1502024. View Article : Google Scholar : PubMed/NCBI

Kazama A, Bilim V, Tasaki M, Anraku T, Kuroki H, Shirono Y, Murata M, Hiruma K and Tomita Y: Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. Sci Rep. 12:203862022. View Article : Google Scholar : PubMed/NCBI

Herrmann T, Ginzac A, Molnar I, Bailly S, Durando X and Mahammedi H: Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: A retrospective study. Cancer Med. 10:6705–6713. 2021. View Article : Google Scholar : PubMed/NCBI

Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, et al: Phase II study of nivolumab and salvage Nivolumab/Ipilimumab in Treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 40:2913–2923. 2022. View Article : Google Scholar : PubMed/NCBI

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, et al: Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 10:e0043162022. View Article : Google Scholar : PubMed/NCBI

Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, et al: Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. J Immunother Cancer. 10:e0052492022. View Article : Google Scholar : PubMed/NCBI

Kato R, Jinnouchi N, Tuyukubo T, Ikarashi D, Matsuura T, Maekawa S, Kato Y, Kanehira M, Takata R, Ishida K and Obara W: TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer. Transl Oncol. 14:1009182020. View Article : Google Scholar : PubMed/NCBI

Koh Y, Nakano K, Katayama K, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T, et al: Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. Int J Urol. 29:462–469. 2022. View Article : Google Scholar : PubMed/NCBI

Incorvaia L, Fanale D, Badalamenti G, Brando C, Bono M, De Luca I, Algeri L, Bonasera A, Corsini LR, Scurria S, et al: A ‘Lymphocyte MicroRNA Signature’ as predictive biomarker of immunotherapy response and plasma PD-1/PD-L1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming. Cancers. 12:33962020. View Article : Google Scholar : PubMed/NCBI

Pan Q, Liu R, Zhang X, Cai L, Li Y, Dong P, Gao J, Liu Y and He L: CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma. Ther Adv Med Oncol. 15:175883592312179662023. View Article : Google Scholar : PubMed/NCBI

Pabla S, Seager RJ, Van Roey E, Gao S, Hoefer C, Nesline MK, DePietro P, Burgher B, Andreas J, Giamo V, et al: Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response. Biomark Res. 9:562021. View Article : Google Scholar : PubMed/NCBI

Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, et al: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 26:688–692. 2020. View Article : Google Scholar : PubMed/NCBI

Ivanova E, Asadullina D, Rakhimov R, Izmailov A, Izmailov A, Gilyazova G, Galimov S, Pavlov V, Khusnutdinova E and Gilyazova I: Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events. Noncoding RNA Res. 7:159–163. 2022. View Article : Google Scholar : PubMed/NCBI

Petitprez F, Ayadi M, de Reyniès A, Fridman WH, Sautès-Fridman C and Job S: Review of prognostic expression markers for clear cell renal cell carcinoma. Front Oncol. 11:6430652021. View Article : Google Scholar : PubMed/NCBI

Lee A, Lee HJ, Huang HH, Tay KJ, Lee LS, Sim SPA, Ho SSH, Yuen SPJ and Chen K: Prognostic significance of inflammation-associated blood cell markers in nonmetastatic clear cell renal cell carcinoma. Clin Genitourin Cancer. 18:304–313. 2020. View Article : Google Scholar : PubMed/NCBI

Teishima J, Inoue S, Hayashi T and Matsubara A: Current status of prognostic factors in patients with metastatic renal cell carcinoma. Int J Urol. 26:608–617. 2019. View Article : Google Scholar : PubMed/NCBI